STAT — The high cost of multiple sclerosis treatments has forced 40% of patients to take "drastic actions" and alter their use of the medicines, such as cutting back or skipping dosages altogether.
multiple sclerosis (MS)
Reuters – The approval allows for production of the drug for the treatment of relapsing forms of multiple sclerosis in adult patients.
OHSU – “I would say the rationales for the price increases are purely what can maximize profit,” one executive said. “There’s no other rationale for it, because costs have not gone up by 10% or 15%; you know, the costs have probably gone down.”
Reuters – The US Food and Drug Administration approved Biogen Inc’s new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.
Food and Drug Administration – The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
CBS News – An experimental treatment for multiple sclerosis is showing promise in stopping symptoms of the disease, according to a new study that found that a single stem cell transplant could stop or delay symptoms better than some medications.
AJMC – The CDC is launching a National Neurological Conditions and Surveillance System (NNCSS) in an effort to help increase understanding of neurological disorders and to further support neurologic research.
Food and Drug Administration – The FDA approved Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.
In this week’s Neuroscience SciPol Weekly, mental health services in the Appalachian region; Trump's plan for opioids; NFL head injuries; and why dolphins and whales have big brains.
In this week's Neuroscience SciPol Weekly, government actions on the opioid crisis; links between a mother's gut microbiome and autism in children; concerns about a common cat parasite; and the neuroscience of nervous habits.